US Department of Veterans Affairs

Company

Related News

GLP-1 Drugs Show Promise in Treating Addiction Across Multiple Substances

A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.

Related Clinical Trials

NCT ID Title Status Phase
NCT07534358

Intensive Case Management Between VA and Community Care for Suicide Prevention

RECRUITING NA
NCT07464834

Postcards to Improve Remote Monitoring Connectivity Among Veterans With a Disconnected Monitor

COMPLETED NA
NCT07296783

Transforming Research and Clinical Knowledge in Geriatric Traumatic Brain Injury (TRACK-GERI)

ENROLLING_BY_INVITATION
NCT07219251

Engagement of Veterans With Lung Cancer

RECRUITING NA
NCT06729606

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

COMPLETED PHASE3
NCT06729593

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

COMPLETED PHASE3
NCT06646614

Group Advanced Care Planning Pilot for Veterans

RECRUITING NA
NCT06571513

Written Exposure Therapy to Improve Recovery Among Sexual Assault Survivors

COMPLETED NA
NCT06441617

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

RECRUITING NA
NCT06403514

The Effects of a Psychoeducational Intervention on Health and Performance-based Outcomes of Veterans Diagnosed With PTSD

COMPLETED NA